Meta CEO Mark Zuckerberg backed-Cellular Intelligence has acquired Danish drugmaker Novo Nordisk's cell therapy candidate for ...

Novo Nordisk A/S agreed to hand over an experimental therapy for Parkinson’s disease to a Mark Zuckerberg-backed AI startup ...

Ozempic maker Novo Nordisk agreed to sell an experimental cell therapy for Parkinson's disease to Cellular Intelligence and take a stake in the U.S. startup, Cellular Intelligence said Monday.

Novo Nordisk (CPSE:NOVO B) has licensed its clinical-stage allogeneic cell therapy program for Parkinson's disease to Cellular Intelligence. The program includes an ongoing Phase 1/2 trial and holds ...

Phase 3 ARISE trial of solengepras, a potential first-in-class non-dopaminergic therapy, is fully enrolled and topline data ...

Cellular Intelligence has licensed Novo Nordisk’s cell therapy programme for Parkinson’s disease, seven months after the ...

Novo Nordisk has sold the rights to one of the flagship candidates in its now-defunct cell therapy unit, which was wound down ...

Researchers identify GPNMB as a driver of Parkinson’s disease spread and demonstrate that monoclonal antibodies can block its activity to slow neurodegeneration.

Classes run by Philly's Tango Therapy Project help people combat the effects of the progressive movement disorder — and gives ...

An intensive voice treatment developed in the USA and known as the Lee Silverman voice treatment (LSVT LOUD) is more effective than conventional NHS speech and language therapy or no therapy for ...

PD, a shelved Parkinson's cell therapy, to AI biotech Cellular Intelligence in return for equity and milestones.